BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lopez-Millan B, Diaz de la Guardia R, Roca-Ho H, García-Herrero CM, Lavoie JR, Rosu-Myles M, Gonzalez-Rey E, O'Valle F, Criado G, Delgado M, Menendez P. Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. Exp Mol Med 2017;49:e290. [PMID: 28154372 DOI: 10.1038/emm.2016.143] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Evangelatos G, Vlachadami I, Kechagia M, Iliopoulos A. Rituximab and lenalidomide combination treatment for rheumatoid arthritis complicated with myelodysplastic syndrome: A case report. Mediterr J Rheumatol 2017;28:217-20. [PMID: 32185287 DOI: 10.31138/mjr.28.4.217] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Liu T, Guo F, Zhu X, He X, Xie L. Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy. Exp Ther Med 2017;14:5251-7. [PMID: 29285050 DOI: 10.3892/etm.2017.5209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
3 Yamamoto K, Kitawaki T, Sugimoto N, Fujita H, Kawase Y, Takaori-Kondo A, Kadowaki N. Anti-inflammatory modulation of human myeloid-derived dendritic cell subsets by lenalidomide. Immunol Lett 2019;211:41-8. [PMID: 31141702 DOI: 10.1016/j.imlet.2019.05.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
4 Lanaro C, Franco-penteado CF, Silva FH, Fertrin KY, dos Santos JL, Wade M, Yerigenahally S, de Melo TR, Chin CM, Kutlar A, Meiler SE, Costa FF. A thalidomide–hydroxyurea hybrid increases HbF production in sickle cell mice and reduces the release of proinflammatory cytokines in cultured monocytes. Experimental Hematology 2018;58:35-8. [DOI: 10.1016/j.exphem.2017.10.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
5 Silva I, Pinto R, Mateus V. Preclinical Study in Vivo for New Pharmacological Approaches in Inflammatory Bowel Disease: A Systematic Review of Chronic Model of TNBS-Induced Colitis. J Clin Med 2019;8:E1574. [PMID: 31581545 DOI: 10.3390/jcm8101574] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
6 Bansal R, Park H, Taborda CC, Gordillo C, Mapara MY, Assal A, Uhlemann AC, Reshef R. Antibiotic exposure, not alloreactivity, is the major driver of microbiome changes in hematopoietic cell transplantation: Antibiotics in auto and allo transplant. Transplant Cell Ther 2021:S2666-6367(21)01448-2. [PMID: 34958974 DOI: 10.1016/j.jtct.2021.12.015] [Reference Citation Analysis]
7 Pervaiz N, Kaur H, Parsad D, Kumar R. Immune modulatory effects of lenalidomide on the cultured peripheral blood mononuclear cells from vitiligo patients. Dermatol Ther 2020;33:e14473. [PMID: 33124184 DOI: 10.1111/dth.14473] [Reference Citation Analysis]
8 Pfrepper C, Poenisch W, Pierer M, Metze M, Kaiser T, Petros S. Inhibitor eradication in refractory acquired hemophilia with lenalidomide. Ann Hematol 2019;98:1533-5. [PMID: 30706086 DOI: 10.1007/s00277-019-03620-2] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Vodusek Z, Feuerstadt P, Brandt LJ. Review article: the pharmacological causes of colon ischaemia. Aliment Pharmacol Ther. 2019;49:51-63. [PMID: 30467871 DOI: 10.1111/apt.15052] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
10 Diaz de la Guardia R, Lopez-Millan B, Lavoie JR, Bueno C, Castaño J, Gómez-Casares M, Vives S, Palomo L, Juan M, Delgado J, Blanco ML, Nomdedeu J, Chaparro A, Fuster JL, Anguita E, Rosu-Myles M, Menéndez P. Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes. Stem Cell Reports 2017;8:1573-86. [PMID: 28528702 DOI: 10.1016/j.stemcr.2017.04.019] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
11 Ouyang W, Zhao X, Lu S, Wang Z. Prevalence of monoclonal gammopathy of uncertain significance in chronic myeloid leukemia: A case report. Medicine (Baltimore) 2018;97:e13103. [PMID: 30383696 DOI: 10.1097/MD.0000000000013103] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 de la Guardia RD, Lopez-Millan B, Roca-Ho H, Bueno C, Gutiérrez-Agüera F, Fuster JL, Anguita E, Zanetti SR, Vives S, Nomdedeu J, Sackstein R, Lavoie J, Gónzalez-Rey E, Delgado M, Rosu-Myles M, Menendez P. Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in in vivo preclinical models of hematopoietic reconstitution and severe colitis. Haematologica 2019;104:e54-8. [PMID: 30237260 DOI: 10.3324/haematol.2018.196568] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
13 Pervaiz N, Kaur H, Parsad D, Kumar R. Immune-modulatory effects of lenalidomide inhibited the progression of lesions in a vitiligo mouse model. Pigment Cell Melanoma Res 2021;34:918-27. [PMID: 33522688 DOI: 10.1111/pcmr.12962] [Reference Citation Analysis]
14 Lopez-Millan B, Diaz de la Guardia R, Roca-Ho H, Anguita E, Islam ABMMK, Romero-Moya D, Prieto C, Gutierrez-Agüera F, Bejarano-Garcia JA, Perez-Simon JA, Costales P, Rovira M, Marín P, Menendez S, Iglesias M, Fuster JL, Urbano-Ispizua A, Anjos-Afonso F, Bueno C, Menendez P. IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML. Oncoimmunology 2018;7:e1477460. [PMID: 30228947 DOI: 10.1080/2162402X.2018.1477460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
15 Heiblig M, Patel BA, Groarke EM, Bourbon E, Sujobert P. Toward a pathophysiology inspired treatment of VEXAS syndrome. Semin Hematol 2021;58:239-46. [PMID: 34802546 DOI: 10.1053/j.seminhematol.2021.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]